---
title: "BIIB.US (BIIB.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BIIB.US/news.md"
symbol: "BIIB.US"
name: "BIIB.US"
parent: "https://longbridge.com/en/quote/BIIB.US.md"
datetime: "2026-05-19T16:13:06.951Z"
locales:
  - [en](https://longbridge.com/en/quote/BIIB.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BIIB.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BIIB.US/news.md)
---

# BIIB.US (BIIB.US) — Related News

### [Immunic names Michael Bonney board chair, replacing interim chair Simona Skerjanec](https://longbridge.com/en/news/286894831.md)
*2026-05-19T10:30:24.000Z*
> Immunic has appointed Michael W. Bonney as chair of the board, effective May 16, 2026, replacing interim chair Simona Sk

### [Boehringer Ingelheim's Phase II clinical trial did not reach the primary endpoint, multiple law firms have initiated securities fraud investigations](https://longbridge.com/en/news/286796113.md)
*2026-05-18T15:55:32.000Z*
> Bojin's stock price plummeted 6.4% on May 14 due to the Phase II clinical trial not meeting its primary endpoint. Severa

### [Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250](https://longbridge.com/en/news/286601918.md)
*2026-05-15T18:35:21.000Z*
> Goldman Sachs analyst Salveen Richter has reiterated a Buy rating on Biogen, raising the price target from $238 to $250.

### [Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, Oppenheimer Analyst Says](https://longbridge.com/en/news/286584470.md)
*2026-05-15T14:49:44.000Z*
> Oppenheimer has raised its price target for Biogen (NASDAQ:BIIB) from $275 to $300, maintaining an 'outperform' rating. 

### [Biogen (NASDAQ:BIIB) Now Covered by Evercore](https://longbridge.com/en/news/286579955.md)
*2026-05-15T14:06:39.000Z*
> Evercore has initiated coverage on Biogen (NASDAQ:BIIB), assigning an 'outperform' rating. Other analysts have also rais